Molecular subtyping of osteosarcoma, ecDNA and more

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/e5/d4/dd/e5d4dd46-be97-333e-098a-4ba20cb1717b/mza_5073955989589906985.jpg/600x600bb.jpg

MIB Agents OsteoBites and osTEAo

MIB Agents Osteosarcoma

197 episodes

4 days ago

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org

Medicine

Health & Fitness

RSS

All content for MIB Agents OsteoBites and osTEAo is the property of MIB Agents Osteosarcoma and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/5010242/5010242-1743015812188-30c716fb0e71e.jpg

Molecular subtyping of osteosarcoma, ecDNA and more

MIB Agents OsteoBites and osTEAo

1 hour 1 minute 57 seconds

5 months ago

Molecular subtyping of osteosarcoma, ecDNA and more

OsteoBites welcomes Yingqi Hua, MD from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine to discuss his work on molecular subtyping of osteosarcoma, ecDNA, and more.
Dr. Hua has been engaged in basic and clinical research of malignant bone tumors for more than 10 years, focusing on the individualized comprehensive treatment of advanced bone tumors, and is committed to transforming research results through clinical research. His research interests include 1. Multi-omics study of osteosarcoma: Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. 2. Epigenetic study of bone tumors: the function of histone mutation and the function of different histone methylation modification. 3. Drug screen: Screening sensitive drugs by patient derived xenograft(PDX) and explore the mechanism of drug action. 4. Clinical trial of advanced stage sarcomas based on precision medicine.